Maharaj, Anil R.
Wu, Huali
Hornik, Christoph P.
Cohen-Wolkowiez, Michael
Funding for this research was provided by:
National Institutes of Health (1R01-HD076676-01A1)
Article History
Received: 6 November 2018
Accepted: 11 April 2019
First Online: 23 April 2019
Compliance with ethical standards
:
: Anil R. Maharaj and Huali Wu have no conflicts of interest to declare. Michael Cohen-Wolkowiez receives support for research from the NIH (5R01-HD076676), NIH (HHSN275201000003I), NIAID/NIH (HHSN272201500006I), FDA (1U18-FD006298), the Biomedical Advanced Research and Development Authority (HHSO1201300009C), and from the industry for the drug development in adults and children (ExternalRef removed). Christoph P. Hornik receives salary support for research from National Institute for Child Health and Human Development (NICHD) (K23HD090239), the U.S. government for his work in pediatric and neonatal clinical pharmacology (Government Contract HHSN267200700051C, PI: Benjamin, under the Best Pharmaceuticals for Children Act), and industry for drug development in children.